E

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022
E

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022
E

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022
E

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022
E

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022
E

Through the keyhole look at an emerging area of drug development

Some important new research which may stimulate a whole new class of anti-cancer therapies

February 28, 2022
E

To degrade or inhibit, that’s the question

The battle over AR antagonists and degraders rages on as new clinical data emerge

February 23, 2022
E

Going after intractable cancer targets

It's time for an update on novel protein degraders

January 11, 2022
E

Can C4 take protein degraders to new heights?

The intriguing science behind a novel protein degrader platform

January 10, 2022
E

Oncology trends and directions to watch out for in 2022

What to watch out for in 2022

January 7, 2022
E

Novel strategies for addressing an intractable cancer target

A look at some cool science and novel strategies for tackling an intractable target

September 2, 2021
E

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021
E

New developments in the protein degradation niche

Update on C4, Kymera, Novartis and Vividion

June 30, 2021
E

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021
E

The battle of protein degraders versus inhibitors continues apace

Who's going to win in the battle between protein degraders and small molecule inhibitors?

May 4, 2021
E

Can a monoDAC hit the groove against IMiDs and CELMoDs?

What can we learn from C4 Therapeutics monoDAC, CFT7455?

April 28, 2021
E

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021
E

The King of Kings

Capturing attention in the crowded protein degradation niche

March 11, 2021
E

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

What to watch out for in the protein degradation niche

March 11, 2021
E

The broad and deep protein degradation landscape

Getting to the centre of things with protein degradation

March 9, 2021
E

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Important learnings from targeted therapies from SABCS

What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS

December 17, 2020
E

The magic of making proteins disappear

A look at Kymera's protein degrader pipeline

July 21, 2020
E

Hematology Winners and Losers at ASCO20

Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.

June 4, 2020
E

What’s new in advanced breast cancer?

There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday

May 26, 2020
E

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020
E

Is the Arvinas PROTAC Proof of the Pudding?

What do we learn from the initial data with novel PROTAC technology?

May 13, 2020
E

JPM20 Highlights from Day 1

Highlights and lowlights from Day 1 of JPM20

January 13, 2020
E

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019
E

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019